Skip to content
Agree.net – Lifestyle
Author:
NeOnc Technologies Holdings, Inc.
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
March 4, 2026